S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:CDXS

Codexis - CDXS Stock Forecast, Price & News

$6.16
-0.35 (-5.38%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.10
$6.50
50-Day Range
$4.26
$6.76
52-Week Range
$4.21
$22.22
Volume
442,855 shs
Average Volume
710,137 shs
Market Capitalization
$404.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.83

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.0% Upside
$19.83 Price Target
Short Interest
Healthy
7.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.43mentions of Codexis in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$657,322 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.56) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

462nd out of 1,026 stocks

Industrial Organic Chemicals Industry

7th out of 20 stocks

CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

15 Worst Stock Picks of Cathie Wood in 2022
Codexis (NASDAQ:CDXS) Rating Increased to Hold at StockNews.com
Escape the Coming Wall Street Meltdown
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? Former Wall Street money manager, Louis Navellier, says all it takes is being on the right side of this force driving the massive divide.
Analysts Set Codexis, Inc. (NASDAQ:CDXS) Price Target at $19.83
Codexis, Inc. (NASDAQ:CDXS) Short Interest Down 7.0% in January
CDXS.P - | Stock Price & Latest News | Reuters
Warning: Biden’s Big Blackout is Coming
Why we are about to RETURN to traditional energy like oil and gas. How the “greenest” Democrats were BUSTED investing in oil and gas. And how you could profit from their failures.
Codexis Third Quarter 2022 Earnings: Beats Expectations
When Should You Buy Codexis, Inc. (NASDAQ:CDXS)?
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
11/04/2021
Today
2/08/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.83
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+222.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-21,280,000.00
Pretax Margin
-23.35%

Debt

Sales & Book Value

Annual Sales
$104.75 million
Book Value
$2.53 per share

Miscellaneous

Free Float
61,089,000
Market Cap
$404.65 million
Optionable
Optionable
Beta
1.56

Key Executives

  • Stephen George Dilly
    President, CEO & Independent Director
  • Kevin Norrett
    Chief Operating Officer
  • Sriram Ryali
    Chief Financial & Accounting Officer
  • Stefan Lutz
    Senior Vice President-Research
  • Karl A. Schoene
    Senior Vice President-Development & Operations













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2023?

4 equities research analysts have issued 12-month price objectives for Codexis' stock. Their CDXS share price forecasts range from $15.00 to $23.00. On average, they predict the company's share price to reach $19.83 in the next twelve months. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the beginning of 2023. Since then, CDXS stock has increased by 32.2% and is now trading at $6.16.
View the best growth stocks for 2023 here
.

Are investors shorting Codexis?

Codexis saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 5,070,000 shares, a decrease of 7.0% from the December 31st total of 5,450,000 shares. Based on an average daily volume of 824,300 shares, the short-interest ratio is currently 6.2 days. Approximately 8.0% of the shares of the company are sold short.
View Codexis' Short Interest
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its earnings results on Thursday, November, 4th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. The biotechnology company earned $36.77 million during the quarter, compared to analysts' expectations of $28.52 million. Codexis had a negative trailing twelve-month return on equity of 19.59% and a negative net margin of 23.49%. The company's revenue for the quarter was up 100.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.10) EPS.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.10 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.45%), ARK Investment Management LLC (6.00%), Sumitomo Mitsui Trust Holdings Inc. (1.66%), Assenagon Asset Management S.A. (1.38%), Allspring Global Investments Holdings LLC (0.87%) and Essex Investment Management Co. LLC (0.49%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $6.16.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $404.65 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 2/9/2023 by MarketBeat.com Staff